A perpetual loser at the high stakes game of Alzheimer’s research, Roche concedes another amyloid flop

The amyloid beta theory that has driven billions of dollars in failed Alzheimer’s research has taken yet another body blow. Roche — and specifically its big sub Genentech — conceded defeat overnight for its closely watched crenezumab in the Phase II API-ADAD trial in Alzheimer’s prevention. This follows twin Phase…

...

Click to view original post